Press Release
2024
2023
2022
2021
2020
Burning Rock Secures Second NGS Kit Approval from the NMPA
GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that the National Medical Products Administration (NMPA) approved Burning Rock’s Human Nine-Gene Mutation Joint Detection...
Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock's OncoCompass™ Target
GUANGZHOU, China, Nov. 17, 2021– Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the...
Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development
Guangzhou, China, August 3, 2021 – Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of...
Burning Rock Announces the Launch of China’s First Prospective Pan-Cancer Multi-omics Early Detection Study
BEIJING, May 19, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced the launch of the PRESCIENT (Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT) study, the first blood-based,...
Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091
GUANGZHOU, China, April 29, 2021-- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”)today announced a strategic partnership with Abbisko Therapeutics (“Abbisko”) in companion diagnostics (CDx). The two companies will work together to develop...
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China
On June 29, 2020, Burning Rock Biotech Limited (NASDAQ: BNR) announced a strategic partnership with CStone Pharmaceuticals (HKEX: 2616) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s...
Burning Rock deepens cooperation with Illumina to promote development and standardization of NGS-based cancer therapy selection [in China]
SHANGHAI, China, May 11, 2020-- Burning Rock and Illumina (NASDAQ: ILMN), a global leader in gene sequencing and array-based technologies, jointly announced today that they are joining forces to promote the development and standardization of NGS-based cancer therapy...
Burning Rock initiates the first prospective, multi-center pan-cancer early detection study in China
SHANGHAI, China, May 07, 2020 (GLOBE NEWSWIRE) -- Burning Rock today announces the initiation of its 14,000 patient PREDICT (Pan-CanceR Early DetectIon ProjeCT) study to further develop and validate its pan-cancer early detection technology. PREDICT will be the first...